Cybin Announces Grant of First U.S. Composition of Matter Patent in Support of its CYB005 Phenethylamines Program

Rhea-AI Summary

Cybin has been granted U.S. patent 12,122,741 by the USPTO for composition of matter claims related to its CYB005 phenethylamines program. The company is investigating these novel molecules at non-hallucinogenic doses for various Central Nervous System disorders. The development includes exploring non-hallucinogenic neuroplastogens and targeted serotonin 5-HT1A and 5-HT2C receptor agonists. This addition brings Cybin's intellectual property portfolio to over 70 granted patents and more than 220 pending patent applications.

Positive

• Secured new U.S. patent strengthening IP protection for CYB005 program
• Extensive IP portfolio with 70+ granted patents and 220+ pending applications
• Expanding development pipeline beyond clinical tryptamine programs

Negative

• None.

Insights

Patent Law Expert

The USPTO grant of composition of matter patent for CYB005 phenethylamines program significantly strengthens Cybin's intellectual property position. This first U.S. patent provides important market exclusivity for their non-hallucinogenic CNS treatment candidates. The patent portfolio's expansion to over 70 granted patents and 220+ pending applications demonstrates robust IP strategy. Composition of matter patents are particularly valuable as they offer the broadest protection for novel chemical compounds, typically lasting 20 years from filing date. This protection is essential for preventing competitors from manufacturing, selling, or using the patented compounds, securing Cybin's market position in the emerging neuropsychiatry space.

Neuropharmacology Expert

The focus on non-hallucinogenic dosing of phenethylamines represents a strategic approach in CNS drug development. The research targeting specific serotonin receptors (5-HT1A and 5-HT2C) shows promise for developing treatments with potentially fewer side effects than traditional psychedelics. Publication in the Journal of Medicinal Chemistry validates the scientific merit of their compound development work. The emphasis on neuroplastogens and targeted receptor agonists suggests a sophisticated understanding of CNS disorder mechanisms, potentially leading to more precise therapeutic interventions with broader market acceptance than hallucinogenic alternatives.

- The Company is evaluating non-hallucinogenic dosing of CYB005 preclinical candidate molecules for the treatment of CNS disorders -

- Cybin’s sector-leading intellectual property portfolio now includes over 70 granted patents and more than 220 patent applications pending -

TORONTO--(BUSINESS WIRE)-- Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry platform company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today announced that the United States Patent and Trademark Office (“USPTO”) has granted U.S. patent 12,122,741 (‘741) with claims to the composition of matter of lead preclinical candidates in the Company's CYB005 phenethylamines program.

The Company is investigating novel molecules within the CYB005 program at non-hallucinogenic doses for a range of Central Nervous System (“CNS”) disorders. In addition, the Company is continuing to explore non-hallucinogenic neuroplastogens within its broader discovery pipeline, as well as targeted serotonin 5-HT_1A and 5-HT_2C receptor agonists.

“The granting of this patent in support of our CYB005 phenethylamines program reinforces our commitment to expanding the breadth of innovative development work beyond our clinical tryptamine programs,” said Doug Drysdale, Chief Executive Officer of Cybin. “Non-hallucinogenic 5-HT receptor agonists have garnered a great deal of attention in recent years, and we are eager to continue exploring their clinical potential in CNS disorders. While our primary focus remains on our clinical-stage psychiatry programs, CYB003 and CYB004, we believe that other programs like CYB005 that target CNS disorders have the potential to address significant unmet medical needs. We remain focused on demonstrating our scientific leadership in the space, while delivering long-term shareholder value.”

The Company previously announced that its research manuscript, entitled “Synthesis and Structure-Activity Relationships of 2,5-dimethoxy-4-substituted phenethylamines and the discovery of CYB210010: A potent, orally bioavailable and long-acting serotonin 5-HT₂ receptor agonist,” was published in the Journal of Medicinal Chemistry, a prestigious bi-weekly peer-reviewed publication of the American Chemical Society.

About Cybin

Cybin is a late-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options to address the large unmet need for people who suffer from mental health conditions.

With industry leading proof-of-concept data, Cybin is working to change the mental health treatment landscape through the introduction of intermittent treatments that provide long lasting results. The Company is currently developing CYB003, a proprietary deuterated psilocin program, about to enter Phase 3 studies for the adjunctive treatment of major depressive disorder and CYB004, a proprietary deuterated DMT program in a Phase 2 study for generalized anxiety disorder. The company also has a research pipeline of investigational, 5-HT-receptor focused compounds.

Founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland. For company updates and to learn more about Cybin, visit www.cybin.com or follow the team on X, LinkedIn, YouTube and Instagram.

Cautionary Notes and Forward-Looking Statements

Certain statements in this news release relating to the Company are forward-looking statements and are prospective in nature. Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as “may”, “should”, “could”, “intend”, “estimate”, “plan”, “anticipate”, “expect”, “believe” or “continue”, or the negative thereof or similar variations. Forward-looking statements in this news release include statements regarding the Company’s belief that CYB005 has the potential to address significant unmet medical needs; and the Company’s proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health disorders.

These forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of the Company to materially differ from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors, among other things, include: implications of the spread of COVID-19 on the Company's operations; fluctuations in general macroeconomic conditions; fluctuations in securities markets; expectations regarding the size of the psychedelics market; the ability of the Company to successfully achieve its business objectives; plans for growth; political, social and environmental uncertainties; employee relations; the presence of laws and regulations that may impose restrictions in the markets where the Company operates; and the risk factors set out in each of the Company's management's discussion and analysis for the three months ended June 30, 2024 and the Company’s annual information form for the year ended March 31, 2024, which are available under the Company's profile on www.sedarplus.ca and with the U.S. Securities and Exchange Commission on EDGAR at www.sec.gov. Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward-looking statements and information contained in this news release. The Company assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.

Cybin makes no medical, treatment or health benefit claims about Cybin’s proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding psilocybin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds. The efficacy of such products has not been confirmed by approved research. There is no assurance that the use of psilocybin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds can diagnose, treat, cure or prevent any disease or condition. Rigorous scientific research and clinical trials are needed. Cybin has not conducted clinical trials for the use of its proposed products. Any references to quality, consistency, efficacy and safety of potential products do not imply that Cybin verified such in clinical trials or that Cybin will complete such trials. If Cybin cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on Cybin’s performance and operations.

Neither the Cboe Canada nor the NYSE American LLC stock exchange have approved or disapproved the contents of this news release and are not responsible for the adequacy and accuracy of the contents herein.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241024410981/en/

Investor & Media Contact:

Gabriel Fahel

Chief Legal Officer

Cybin Inc.

1-866-292-4601

irteam@cybin.com – or – media@cybin.com

Source: Cybin Inc.

FAQ

What is the new U.S. patent granted to Cybin (CYBN) for its CYB005 program?

Cybin was granted U.S. patent 12,122,741 for composition of matter claims related to lead preclinical candidates in its CYB005 phenethylamines program.

How many patents does Cybin (CYBN) currently hold in its portfolio?

Cybin's intellectual property portfolio includes over 70 granted patents and more than 220 patent applications pending.

What is Cybin (CYBN) investigating with its CYB005 program?

Cybin is investigating novel molecules within the CYB005 program at non-hallucinogenic doses for various Central Nervous System (CNS) disorders.